The relapsed or refractory diffuse large B-cell lymphoma market has witnessed significant growth over the past few years owing to the increasing prevalence of lymphoma across the globe. Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma that affects B-cells and accounts for around 30% of newly diagnosed cases of non-Hodgkin lymphoma. Despite advances in upfront treatment options like combination chemoimmunotherapy, up to 40% of patients experience relapse or ... Read more
